Magnus uses viable spine-derived cells from the vertebral region and preserves them with a DMSO-free cryoprotectant. DMSO has been linked to post-transplant complications. Surgeons can use Magnus in bone graft-based procedures.
Researchers studied the Magnus Viable Allograft’s performance in 75 consecutive TLIF fusions. The procedure had a 96 percent fusion rate, with 75 patients undergoing a total of 85 levels fused at 12 months, according to a study published in the International Journal of Spine Surgery.
More articles on practice management:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.